GVR Report cover Women's Health Therapeutics Market Size, Share & Trends Report

Women's Health Therapeutics Market Size, Share & Trends Analysis Report By Type (Infection, Pregnancy, Oncology), By Region (North America, Europe, APAC, LATAM, MEA), And Segment Forecasts, 2018 - 2025

  • Report ID: GVR-2-68038-414-7
  • Number of Report Pages: 140
  • Format: PDF, Horizon Databook
  • Historical Range: 2014 - 2017
  • Forecast Period: 2018 - 2025 
  • Industry: Healthcare

Industry Insights

The global women’s health therapeutics market size was valued at USD 108.0 billion in 2017 and is expected to expand at a CAGR of 8.8% over the forecast period. Continuous rise in prevalence of chronic and lifestyle-associated disorders in women is likely to propel market growth. In addition, growing healthcare investment for early detection of cancer and infectious diseases, complications related to pregnancy, and launch of new and effective drugs are likely to further drive the market.

U.S. womens health therapeutics market

Growing awareness regarding cancer, menopause, osteoporosis, and infections is expected to drive the market for women’s health therapeutics. Moreover, introduction of new drug therapies by major market players is likely to contribute to market expansion in the forthcoming years. For instance, in March 2017, TESARO, Inc. received the U.S. Food and Drug Administration (FDA) approval for Zejula, which is used for treatment of advanced ovarian cancer.

In 2015, the World Health Organization (WHO) released guidelines recommending people living with HIV in South Africa to be provided with Antiretroviral Therapy (ART) immediately following diagnosis, regardless of the CD4 count. South Africa has begun implementing this recommendation, which is also known as Test and Treat Policy for HIV.Governments and private companies are increasing their investment to improve women’s healthcare especially for ovarian, cervical, uterine, and breast cancers; multiple sclerosis; and others. For instance, in May 2018, LYNPARZA (olaparib) received approval from the European Union (EU) to treat platinum-sensitive relapsed ovarian cancer.

Furthermore, factors like business collaborations, mergers and acquisitions, funding, and product approvals are projected to boost the market during the forecast period. For instance, in June 2018, Eli Lilly and Company completed the acquisition of ARMO BioSciences, Inc. The acquisition assisted Eli Lilly to add promising immunotherapeutic agents to their oncology product portfolio. In May 2018, Pharmascience, Inc. launched (Pr) PMS-NITROFURANTOIN capsules for the treatment of urinary tract infection. This launch will enable Canadian women to access effective treatment and propel overall growth of the market.

Type Insights

Based on type, the women’s health therapeutics market is segmented into infection, pregnancy, and oncology. Oncology is sub-segmented into cervical, ovarian, uterine, and vaginal and vulvar cancer. The infection segment dominated the market in 2017 due to increase in incidence of bacterial vaginosis (BV), tuberculosis (TB), herpes simplex virus, toxoplasmosis, cytomegalovirus, urinary tract infection (UTI), and hepatitis A, B, C, D, and E. According to the Centers for Disease Control and Prevention (CDC), BV is the most prevalent infection among women in U.S., affecting around 21.2 million women (age 14 to 49) annually.

Cervical cancer held a majority of the revenue share within the oncology segment in 2017 and is likely to maintain its position during the forecast period. Product approvals, new product launches, increase in clinical trials, and available reimbursement for better and effective treatment are some of the major driving factors for this expansion. Merck and Co. received FDA approval for its KEYTRUDA drug for the treatment of cervical cancer in June 2018. In April 2015, F. Hoffmann-La Roche Ltd. received approval in Europe for Avastin (bevacizumab), to be taken in combination with standard chemotherapy.

Ovarian cancer is expected to witness the fastest CAGR during the forecast period owing to increase in incidence of ovarian cancer and adoption of advanced diagnostic techniques to increase the treatment rate. According to the American Cancer Society, in 2017, 14,080 women died, 22,440 women were diagnosed with ovarian cancer in U.S.

Regional Insights

North America was the dominant regional market for women’s health therapeutics in 2017. This can be attributed to rising cases of chronic diseases, increased funding, and mergers and acquisitions. According to the Connecticut Small Business Development Center, GestVision, Inc. received a funding of USD 2 million for a diagnostic test of preeclampsia among pregnant woman in 2015. In September 2017, Quest Therapeutics acquired outreach lab services operations of two hospitals, namely, the Hospital of Central Connecticut and the William W. Backus Hospital, of Hartford HealthCare (HHC). This acquisition will enable patients and physicians to directly access testing services for timely treatment and care.

Global womens health therapeutics market

Asia Pacific is estimated to be the fastest-growing region during the forecast period. Increase in per capita income, prevalence of chronic diseases, aging population, and product approvals, has encouraged early diagnosis and treatment. In January 2018, GlaxoSmithKline (GSK) received approval from China Food and Drug Administration for Triumeq— a single-pill, low-cost treatment for HIV. It can reduce the burden of expensive treatments in China.

Brazil dominated the Latin America region in 2017. Increasing geriatric population and incidence of cancer and other chronic conditions among women coupled with government initiatives to tackle women-related health are the major regional market drivers.

Women’s Health Therapeutics Market Share Insights

Key market contributors are Bayer AG; Pfizer, Inc.; Teva Pharmaceutical; and F. Hoffmann-La Roche Ltd. Teva Pharmaceutical has more than 1,800 generic products. They acquired Actavis Generics in August 2016 to further expand their generic medicines portfolio. The company offers specialty drugs such as ParaGard and Plan B One-Step pertaining to therapeutics. In July 2017, Teva launched Vagifem used for treatment of atrophic vaginitis.

In May 2018, Pfizer entered into Phase III trial for Avelumab that can be used in combination with chemotherapy to treat ovarian cancer. This is expected to boost their treatment services as well as deliver high-quality care to consumers and communities.

Report Scope



Base year for estimation


Actual estimates/Historical data

2014 - 2017

Forecast period

2018 - 2025

Market representation

Revenue in USD Million and CAGR from 2018 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Country scope

U.S., Canada, U.K., Germany, France, Spain, Italy, Japan, China, India, Brazil, Mexico & South Africa

Report coverage

Revenue forecast, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels, and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global women’s health therapeutics market report on the basis of type and region:

  • Type Outlook (Revenue, USD Million, 2014 - 2025)

    • Infection

    • Pregnancy

    • Oncology

      • Cervical Cancer

      • Ovarian Cancer

      • Uterine Cancer

      • Vaginal & Vulvar Cancer

  • Regional Outlook (Revenue, USD Million, 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

      • France

      • Spain

      • Italy

    • Asia Pacific

      • China

      • Japan

      • India

    • Latin America

      • Brazil

      • Mexico

    • Middle East & Africa

      • South Africa

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.